PhagoMed Biopharma GmbH is a biotech company focused on the development of human therapeutic applications of phage therapy.

Its development programs are based on the last-resort treatment experiences of its clinical cofounders with phages as well as research collaborations with highly prestigious scientists and research institutions in Germany (Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures GmbH, Braunschweig, and Justus-Liebig-Universität Giessen) and Belgium (Ghent University).

In 2018, PhagoMed raised more than €4 million in seed funds and public grants.

Currently, PhagoMed employs six highly qualified employees at the Campus Vienna BioCenter in Vienna, Austria.